[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. Louis University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":371},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,57,86,118,138,165,193,218,243,272,296,323,350],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100642883","effects-of-caffeine-on-chess-performance-and-cognitive-function-in-professional-chess-players-100642883",false,"NCT07641335","Effects of Caffeine on Chess Performance and Cognitive Function in Professional Chess Players","GRANDMASTER: Gauging the Role of Alertness and Neurostimulation With Dietary Caffeine in Master-Level Chess; A Double-Blind Randomized Crossover Trial","GRANDMASTER","Inclusion Criteria:\n\n* Male and female professional chess players aged 18-50 years\n* Current Fédération Internationale des Échecs (FIDE) standard rating between 2300 and 2600 Elo, or achievement of a standard FIDE rating within this range during the previous 12 months\n* Habitual caffeine consumers consuming ≤2 cups of coffee per day\n* Willingness to comply with all study procedures and study visits\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Non-caffeine users\n* Habitual caffeine intake exceeding 2 cups of coffee per day\n* Cardiovascular disorders\n* Metabolic disorders\n* Psychiatric disorders\n* Pregnancy or breastfeeding\n* Current smoking\n* Shift workers\n* Use of psychoactive medications\n* Participation in another clinical trial within the previous 3 months\n* Known allergy or intolerance to milk proteins, dairy products, or soy\n* Known red-green color blindness or other color vision deficiencies that may interfere with Stroop Test performance",true,"ALL","18 Years","50 Years",{"count":22,"type":23},12,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study will examine whether caffeine improves cognitive and competitive performance in professional chess players during tournament-style games. In a randomized double-blind crossover design, participants will complete two experimental sessions in which they consume either caffeinated coffee or decaffeinated coffee before playing a standardized chess match. Cognitive performance will be assessed using attention and reaction-time tests, including the Stroop Test, Trail Making Test, and Puzzle Rush task. Chess performance outcomes such as move accuracy, time management, and error rates will also be evaluated. The study aims to determine whether moderate caffeine intake enhances focus, alertness, and decision-making during prolonged competitive chess play.",[29,30,31,32],"Cognitive Performance","Attention","Reaction Time","Caffeine",[32,34,29,30,35,36,37,38,39,40,41,42,43],"Chess Performance","Mental Fatigue","Professional Chess Players","Decision Making","Neurocognitive Performance","Randomized Crossover Trial","Coffee","Alertness","Executive Function","Cognitive Fatigue","NOT_YET_RECRUITING","2026-06-08",{"date":47,"type":48},"2026-06-11","ACTUAL",{"date":50,"type":23},"2026-06-15",{"date":52,"type":23},"2027-08",{"name":54,"class":55},"St. Louis University","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":64,"minAge":19,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":24,"phases":68,"briefSummary":70,"conditions":71,"keywords":74,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":56},"100458439","phase-2-testosterone-treatment-in-men-with-chronic-kidney-disease-100458439","NCT05249634","Testosterone Treatment in Men With Chronic Kidney Disease","Effect of JATENZO® Therapy on Testosterone and Hemoglobin Concentrations in Hypogonadal Men With Chronic Kidney Disease","Inclusion Criteria:\n\n* Men between ages of 18-85 years of age\n* eGFR 15-45 ml\u002Fmin\u002F1.73m2 by MDRD (Modification of Diet in Renal Disease) equation\n* Subnormal total serum T concentrations (\\\u003C300 ng\u002Fdl) on two separate occasions in morning\n* Symptoms of hypogonadism (as per Endocrine Society guidelines): low libido, erectile dysfunction, fatigue, irritability, depressed mood, poor concentration, increased body fat, decreased muscle bulk, reduced physical performance, sleep disturbance, loss of body hair (15)\n* Normal iron stores as defined by serum ferritin ≥100 ng\u002FmL and transferrin saturation (TSAT) ≥20%.\n\nExclusion Criteria:\n\n* Use of TRT currently or in the past 6 months, including use of over-the-counter androgen containing health supplements (e.g., DHEA)\n* Hematocrit \\>48% (as per Endocrine Society guidelines)(15)\n* Treatment with erythropoiesis stimulating agents (ESA)\n* Uncontrolled blood pressure (\\>180\u002F100 mm Hg)\n* Heart Failure, class III or IV\n* Myocardial infarction, stroke, or heart surgery in the past 3 months\n* Breast cancer\n* History of prostate cancer\n* Prostate specific antigen (PSA) \\>4 ng\u002Fml, unless prostate cancer has been ruled out by a urologist (documented in physician notes)\n* HIV or untreated hepatitis C\n* Untreated, severe obstructive sleep apnea\n* Initiated iron replacement in the last 3 months\n* deep venous thrombosis or pulmonary embolism in the last 3 months\n* recurrent (more than once) deep venous thrombosis or pulmonary embolism\n* use of warfarin\n* Planning to have children in the next one year","MALE","85 Years",{"count":67,"type":23},20,[69],"PHASE2","This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).",[72,73],"Hypogonadism, Male","Kidney Disease, Chronic",[75,76],"testosterone","CKD","RECRUITING","2026-04-24",{"date":80,"type":48},"2026-04-30",{"date":82,"type":48},"2022-03-15",{"date":84,"type":23},"2028-12",{"name":54,"class":55},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":24,"phases":94,"briefSummary":96,"conditions":97,"keywords":103,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":56},"100348956","phase-3-post-op-pain-control-for-prophylactic-intramedullary-nailing-100348956","NCT03823534","Post-Op Pain Control for Prophylactic Intramedullary Nailing.","Inclusion Criteria:\n\n1. Femoral Shaft or Neck bone lesion\n2. 18 years old or greater\n3. Plan to undergo prophylactic intramedullary nailing of one femur\n\nExclusion Criteria:\n\n1. Concurrent pathologic fracture\n2. History of advanced renal impairment (eGFR\\\u003C30mL\u002Fmin)\n3. History of Peptic Ulcer Disease with bleeding or requiring hospitalization\n4. History of NSAID or aspirin allergy\n5. Concurrent chemotherapy regimen that prevents NSAID use\n6. History of liver disease that precludes use of toradol\n7. History of heart failure or cardiovascular disease that precludes toradol usage\n8. Pregnancy\n9. History of narcotic allergy resulting in anaphylaxis\n10. Patients with coagulation disorders or those who require concomitant use of anticoagulant or anti- platelet therapy during the treatment phase of the study.\n11. Patients with acetaminophen allergies resulting in anaphylaxis\n12. Current use of the medication probenecid\n13. Current use of the medication Pentoxifylline\n14. History of aspirin induced asthma.\n15. Known history of opioid dependence, abuse, or addiction.\n16. Bilateral IMN of the femurs",{"count":93,"type":23},60,[95],"PHASE3","Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to NSAID use. Orthopedic oncology, however, has a unique subset of patients that undergo prophylactic placement of intramedullary femoral nails. Because no fracture is present, these patients do not rely on inflammatory healing factors, allowing for post-op NSAID use. This study sets out to determine the effect of post-op toradol use in addition to opioids compared to solely opioids in patients undergoing prophylactic nailing of the femur.",[98,99,100,101,102],"Bone Metastases","Lymphoma","Multiple Myeloma","Opioid Use","Pain",[104,105,106,107,108,109],"Toradol","Ketorolac","Prophylactic intramedullary nail","bone metastases","Opioid use","post-operative pain","2026-04-17",{"date":112,"type":48},"2026-04-22",{"date":114,"type":48},"2019-02-20",{"date":116,"type":23},"2027-03-31",{"name":54,"class":55},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":24,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":131,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100308490","phase-3-local-bisphosphonate-effect-on-recurrence-rate-in-extremity-giant-cell-tumor-of-bone-100308490","NCT03295981","Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone","Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Primary benign GCT of bone\n* Lesion located in an extremity\n* Lesion amenable to reconstruction (intralesional curettage) defined as having at least one intact column of bone after removal\n* No previous systemic bisphosphonate or denosumab therapy\n\nExclusion Criteria:\n\n* Recurrent GCT of bone\n* Non-extremity location\n* Lesion too extensive for intralesional treatment, either due to bone loss, joint invasion, or large soft tissue component\n* Children and pregnancy\n* Previous systemic bisphosphonate or denosumab therapy",{"count":126,"type":23},120,[95],"The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.",[130],"Giant Cell Tumor of Bone",{"date":112,"type":48},{"date":133,"type":48},"2018-05-03",{"date":135,"type":23},"2028-01",{"name":54,"class":55},16,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":64,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":24,"phases":146,"briefSummary":147,"conditions":148,"keywords":153,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":56},"100624227","reduction-of-bacterial-seeding-in-total-shoulder-arthroplasty-100624227","NCT07406893","Reduction of Bacterial Seeding in Total Shoulder Arthroplasty","Reduction of Bacterial Seeding in Total Shoulder Arthroplasty: Prontosan Antimicrobial Gel Incision Preparation Versus No Preparation in Male Patients","Inclusion Criteria:\n\n* Adult male 18 years of age or older undergoing elective primary total shoulder arthroplasty, including both anatomic and reverse total shoulder arthroplasty, for indications including massive rotator cuffs, rotator cuff arthropathy, glenohumeral osteoarthritis, and acute fractures.\n\nExclusion Criteria:\n\n* Any revision shoulder arthroplasty procedure or other shoulder surgery that is not a primary shoulder arthroplasty.\n* Patients with allergy to active ingredients in Prontosan gel\n* Patient is unable to consent for themselves\n* Patient is non-English speaking\n* Females",{"count":93,"type":23},[26],"The purpose of this study is to compare the growth of intra-operative tissue cultures of Cutibacterium Acnes after primary shoulder replacement when using a no-prep control group versus Prontosan wound gel applied to the skin layer after the skin incision has been made.",[149,150,151,152],"Joint Arthroplasty","Shoulder","Cutibacterium Acnes","Prosthetic Joint Infection",[154,155,156],"Antimicrobial wound gel","Dermal layer","Skin preparation","2026-03-06",{"date":159,"type":48},"2026-03-10",{"date":161,"type":48},"2026-02-23",{"date":163,"type":23},"2026-12",{"name":54,"class":55},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":18,"minAge":172,"maxAge":20,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":177,"conditions":178,"keywords":181,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":56},"100605127","phase-4-efficacy-of-methylprednisolone-for-pain-control-after-acl-repair-100605127","NCT07158476","Efficacy of Methylprednisolone for Pain Control After ACL Repair","Efficacy of Methylprednisolone for Pain Control After ACL Repair: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patient undergoing ACL repair or ACL reconstruction with tendon autograft\n* Age 13-50 years old\n* Able to provide informed consent or parent\u002Flegal guardian is able for minors\n\nExclusion Criteria:\n\n* Concurrent and significant injury to other bones or organs (Injury Severity Score of 4 or greater)\n* Revision ACL reconstruction\n* Concomitant additional ligament reconstruction or high tibial osteotomy\n* A history of alcohol abuse, substance abuse or chronic opioid use (filled opioid medication ×2 within 6 months of the surgery)\n* A history of renal failure (\\\u003C60 mL\u002Fmin\u002F1.73 m2), liver dysfunction (child class, \\>B), severe heart disease (NYHA Class 4), diabetes, neurological or psychiatric diseases that may affect pain perception, and pre-existing immune suppression.\n* A history or active peptic ulcer disease, gastrointestinal bleeding, or current use of anticoagulation.\n* Patients currently taking oral or injectable glucocorticoids and those who have taken either within 1 month of the procedure.\n* Patients who are currently pregnant.\n* Patients who are unable to undergo the multimodal pain standardized protocol including those with comorbidities or medical allergies precluding the use of corticosteroids, gabapentin, hydrocodone, acetaminophen, ketorolac, and\u002For meloxicam.","13 Years",{"count":174,"type":23},90,[176],"PHASE4","Opioids are commonly used after orthopedic surgery for pain control but have been shown to increase complications, surgeries, readmissions, and risk for opioid use disorder. The purpose of this study is to investigate the impact of adding a methylprednisolone taper to the pain regimen after ACL repair surgery to determine if this results in decreased postoperative pain and opioid use without increasing complications.",[179,180],"ACL Surgery","Pain Management",[182,183,184],"pain","opioids","orthopedic surgery","2025-10-22",{"date":187,"type":48},"2025-10-24",{"date":189,"type":48},"2025-10-21",{"date":191,"type":23},"2031-09",{"name":54,"class":55},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":24,"phases":203,"briefSummary":204,"conditions":205,"keywords":207,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":56},"100494429","map-for-coaches-translating-sports-injury-prevention-knowledge-to-youth-sport-coaches-100494429","NCT05718063","MAP for Coaches: Translating Sports Injury Prevention Knowledge to Youth Sport Coaches","MAP for Coaches: A Web-Based Musculoskeletal Athletic Injury Prevention Training Course to Increase the Routine Use of Neuromuscular Training Warm-Up Programs","MAP","Inclusion Criteria:\n\n* Active and ongoing engagement in team youth sport coaching\n* Member of a youth sport organization in the United States\n* Must be a team sport coach for one of the following: soccer, basketball, football or volleyball\n\nExclusion Criteria:\n\n* Additional engagement in adult coaching\n* No email address contact",{"count":202,"type":23},200,[26],"The goal of this clinical trial is to test the effectiveness of the MAP for Coaches, a web-based Musculoskeletal Athletic injury Prevention training course, in youth sport coaches. The main question it aims to answer are:\n\n* Is the MAP for Coaches effective in increasing coaches' sport-specific knowledge of musculoskeletal injuries (types, incidence, risk factors, mechanisms, and best prevention practices, with focus on neuromuscular training warm-up exercise programs)?\n* Is the MAP for Coaches effective in increasing coaches' motivation (self-efficacy and intention) to use sport-specific neuromuscular training warm-up exercise programs?\n\nThe additional questions it aims to answer are:\n\n* Are the effects of the MAP for Coaches sustained in the short- and long-term?\n* Is the MAP for Coaches effective in promoting the use of sport-specific neuromuscular training warm-up exercise programs in youth sport coaches?\n\nRegardless of group, participants will receive the MAP for Coaches eLearning training course; however, the participants allocated to the control group will have their post-test survey completed right after they review the sport-specific 2-page injury prevention e-book containing an overview of the MAP for Coaches training course, including an infographic summary (Summarized MAP for Coaches eLearning Training Course). The intervention group will complete the post-test survey after the full training including both the course summary and the detailed course modules (the full training).\n\nThe investigators will compare the two groups to see if an exposure to the (Full) MAP for Coaches eLearning Training Course improves study outcomes compared with the control group.",[206],"Knowledge, Attitudes, Practice",[208,209,210],"Dissemination and Implementation","Neuromuscular Training Exercise Warm-up","Technology-Enabled Knowledge Translation","2025-09-26",{"date":213,"type":48},"2025-10-02",{"date":215,"type":48},"2023-08-08",{"date":163,"type":23},{"name":54,"class":55},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":17,"sex":226,"minAge":19,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":24,"phases":229,"briefSummary":230,"conditions":231,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":56},"100401814","mindfulness-in-endometrial-and-cervical-cancer-100401814","NCT04512144","Mindfulness in Endometrial and Cervical Cancer","Mindfulness Practice in Endometrial and Cervical Cancers With Smartphone Applications (MECCA)","MECCA","Inclusion Criteria:\n\n* New diagnosis of either 1) endometrial cancer undergoing surgery or 2) cervical cancer undergoing chemo-sensitizing radiation\n* Access to a smartphone\n\nExclusion Criteria:\n\n* Non-English speaking\n* No access to smartphone\n* Current use of Headspace application","FEMALE","90 Years",{"count":126,"type":23},[26],"Patients with endometrial cancer who will be undergoing surgery or patients with cervical cancer who will be treated with chemoradiation will be randomized to utilize the Headspace smartphone application or not prior to their anticipated treatment.",[232,233,234,235,101],"Gynecologic Cancer","Endometrial Cancer","Cervical Cancer","Quality of Life",{"date":237,"type":48},"2025-09-30",{"date":239,"type":48},"2020-07-25",{"date":241,"type":23},"2026-07-30",{"name":54,"class":55},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":24,"phases":252,"briefSummary":253,"conditions":254,"keywords":257,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":56},"100594860","short-term-effects-of-caffeine-and-a-multi-ingredient-pre-workout-on-exercise-performance-100594860","NCT07024940","Short-term Effects of Caffeine and a Multi-ingredient Pre-workout on Exercise Performance","Acute Effects of Coffee, Anthocyanin-Caffeine Supplement and Placebo on Exercise Performance Markers","Inclusion Criteria:\n\n* Are a healthy male or female adult aged 18-35 years old\n* Regularly engaged in resistance training or aerobic exercise at least 3 times per week, at least 30 minutes a week for the past 6 months\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Have a history of or currently have a cardiovascular or metabolic disease (e.g., diabetes, prediabetes, hypertension, arrhythmia, heart attack, stroke, non-alcoholic fatty liver disease, chronic kidney disease)\n* History of seizure disorder\n* Currently taking prescription medications (e.g., beta-blockers, antidepressants, anti-anxiety, pain killers)\n* Currently pregnant, breastfeeding, pregnant within the past year, or a chance of being pregnant\n* Recent participation in another clinical trial\n* Any sensitivities to caffeine, coffee, berries, maltodextrin, monk fruit extract, or any known food allergies\n* Currently undertaking serious exercise training (6 or more days of the week)\n* Recently started taking creatine or beta-alanine daily within the past 3 months. (If greater than 3 months taken consistently is okay)","35 Years",{"count":22,"type":23},[26],"The investigators are conducting a study to see how a commercial pre-workout supplement, coffee, and water affect how well people perform. The study is conducted across four visits. The first visit is to assess the participants, and the next three visits are for testing. Each participant will drink a randomly assigned beverage 45 minutes before testing. Throughout the study, the participants will complete three testing days-each at least three days apart-so they can try all three drinks. The first test is the Wingate test, where the participants pedal as fast as they can for 30 seconds against a set resistance. The second test is a 1-mile treadmill run\u002Fwalk on an incline, where the participant tries to complete the distance as fast as possible. The third test measures reaction time using light-up buttons to see how quickly a participant responds by touching them. These tests will help determine if any of the drinks improve performance. The results can help people choose the best drink for their workouts or races.",[40,255,256],"Anthocyanins","Exercise Performance",[40,32,258,259,260,261,262,263],"Wingate","Anthocyanin-Caffeine","1-mile","VO2 max","pre-workout","supplement","2025-08-15",{"date":266,"type":48},"2025-08-19",{"date":268,"type":48},"2025-04-25",{"date":270,"type":23},"2026-09-01",{"name":54,"class":55},{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":226,"minAge":19,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":24,"phases":281,"briefSummary":282,"conditions":283,"keywords":285,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":56},"100504938","preconception-intervention-for-incarcerated-women-with-substance-use-100504938","NCT05854836","Preconception Intervention for Incarcerated Women With Substance Use","A Preconception Health Intervention to Reduce Substance Exposed Pregnancies Among Incarcerated Women","Inclusion Criteria:\n\n* English-speaking\n* Capable of becoming pregnant (did not undergo a permanent sterilization procedure and not using a highly effective long-acting reversible birth control method, i.e. intrauterine device or implant.)\n* During the three year prior to arrest or entering the treatment program engaged in vaginal sex with a male partner.\n* During the three months prior to arrest or entering the treatment program used at least one substance (heroin, fentanyl, opioids, cocaine, methamphetamine, or marijuana or alcohol with another substance).\n* (For women recruited from the MAT Program): Expected length of incarceration at the St. Louis County Jail 2-6 months; expected release into the community.\n\nExclusion Criteria:\n\n* Participated in a focus group that was part of the formative work for this study to create the intervention adaptation\n* Non-English-speaking\n* Not capable of pregnancy (underwent a permanent sterilization procedure or using a long-acting reversible contraceptive method)\n* No vaginal sex with a male partner in the 3 years prior to incarceration or entering the treatment program.\n* No use of an illicit substance, such as only alcohol or marijuana use not in combination with another substance","49 Years",{"count":174,"type":23},[26],"The goal of this pilot trial is to test the feasibility and acceptability as well as efficacy of the adapted intervention, CHOICES-PLEAS (Pregnancy Liberated from Exposure to Alcohol and Substances) among women will illicit polysubstance use participating in a court-mandated jail-based 90-day substance use disorder treatment program. The main questions it aims to answer are:\n\n1. What is the feasibility and acceptability of implementing the CHOICES-PLEAS intervention in a court-mandated jail-based substance use disorder treatment program?\n2. Does participation in CHOICES-PLEAS lower the risk of a substance exposed pregnancy at 1 and 3 months after release compared to a control condition?\n3. Does participation in CHOICES-PLEAS increase motivation to change substance use and reduce risky sexual behaviors at 1 and 3 months after release compared to a control condition? Participants will receive three one-on-one motivational interviewing sessions and one family planning referral visit during incarceration and one booster session at 1 month after release from jail.\n\nResearchers will compare the CHOICES-PLEAS intervention to a control condition to see if participation in the intervention reduces risk of substance exposed pregnancy, increases motivation to change substance use, and reduces risk of risky sexual behaviors.",[284],"Substance Use Disorders",[284,286,287],"Preconception Health","Motivational Interviewing","2025-07-17",{"date":290,"type":48},"2025-07-22",{"date":292,"type":48},"2023-12-04",{"date":294,"type":23},"2027-03-01",{"name":54,"class":55},{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":18,"minAge":302,"maxAge":65,"enrollmentInfo":303,"targetDuration":4,"studyType":24,"phases":305,"briefSummary":306,"conditions":307,"keywords":310,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":56},"100582147","step-up-to-pd-a-community-based-walking-program-for-people-with-parkinsons-disease-100582147","NCT06859528","Step Up to PD: A Community-based Walking Program for People With Parkinson's Disease","Inclusion Criteria:\n\n* 30-85 years old\n* Neurologist-diagnosed Parkinson's disease\n* Able to walk independently with or without a walking aid (e.g., cane, walker)\n* Willing to participate in study for at least 6 months\n\nExclusion Criteria:\n\n* Health diagnosis that would limit exercise participation (e.g., heart problems, uncontrolled blood pressure, exercise-induced asthma).\n* Additional neurologic disease or injury beyond Parkinson's disease.\n* Evidence of significant cognitive impairment. This will be determined by completing the Montreal Cognitive Assessment\n* Participants with poor walking ability (determined using the Timed Up and Go Test during initial testing).","30 Years",{"count":304,"type":23},40,[26],"This study will investigate the feasibility of a 6-month community walking program for people with Parkinson's disease (PD) and their care partners in greater Saint Louis, Missouri region. The walking program will consist of weekly, organized walking groups at the Missouri Botanical Gardens. Participants in the program will use Nordic walking poles during the walks. The walking group(s) will meet once per week and will be supervised by walking group leaders from Saint Louis University. Participants will be given a smart watch to wear that will help step counts will be tracked in real-time. The program is designed to get people with Parkinson's disease out of their homes, cultivate a culture of connection with others with Parkinson's disease, and to be collectively accountable for a common goal toward increasing their physical and social engagement in their communities.",[308,309],"Parkinson Disease","Parkinson Disease, Idiopathic",[311,312,313,314],"Walking","Physical Activity","Social Connectedness","Loneliness","2025-05-12",{"date":317,"type":48},"2025-05-14",{"date":319,"type":48},"2025-04-01",{"date":321,"type":23},"2027-09-30",{"name":54,"class":55},{"id":324,"slug":325,"hasResults":11,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":227,"enrollmentInfo":330,"targetDuration":4,"studyType":332,"phases":4,"briefSummary":333,"conditions":334,"keywords":340,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":56},"100489679","apol1-genetic-testing-in-african-americans-100489679","NCT05656261","APOL1 Genetic Testing in African Americans","APOL1 Genetic Testing in African Americans: Exploring Attitudes About Genetic Risk to Improve Comprehensive Kidney Risk Assessment for Patients and Families","Inclusion Criteria:\n\n* Ages 18-90\n* Self-Identified as Black\u002FAfrican American. Race will be self-identified. Patients of African ancestry who identify as multi-racial are also eligible to participate.\n\nExclusion Criteria:\n\n* Cognitively impaired\u002Funable to provide consent\n* Terminally ill\n* Renal replacement therapy (RRT), e.g., (but not limited to) hemodialysis, peritoneal dialysis",{"count":331,"type":23},600,"OBSERVATIONAL","Recent breakthroughs in medical genetics have discovered that a portion of kidney failure affecting the Black community is mediated by coding variants in a gene called apolipoprotein L1 (APOL1) - and that genetic variants, not race - account for increased risk. For APOL1 genetic testing to be applied in a manner that improves patient care and outcomes, more information is needed regarding associations of genotype with clinical parameters related to kidney health. Further, understanding patient perceptions about knowledge of the results of APOL1 genetic testing, and how that impacts patient engagement with management of hypertension and other renal risk factors, is urgently needed.\n\n* In a Phase 1 pilot study, we offered APOL1 genetic testing to Black patients seen in our Hypertension and Nephrology clinics at Saint Louis University, an academic medical center that serves the local urban community, and surveyed patients on attitudes and concerns about APOL1 genetic testing. 144 participants were enrolled in Phase 1.\n* In the Phase 2 study, we will advance this important work in our community by offering participation to a broader patient base, including patients seen in Internal and Family Medicine clinics, SLU Hospital, as well as to first-degree relatives and spouses of SLUCare participants. This expansion seeks to advance understanding of environment-gene interactions, improve risk prediction, and target management of potentially modifiable risk factors.",[335,336,337,338,339],"Genetic Predisposition","Chronic Kidney Diseases","Nephropathy","APOL1 Associated Kidney Disease","Disparities",[341],"APOL1 Renal Risk Variants","2025-03-17",{"date":344,"type":48},"2025-03-20",{"date":346,"type":48},"2019-01-24",{"date":348,"type":23},"2027-06-30",{"name":54,"class":55},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":354,"acronym":355,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":227,"enrollmentInfo":357,"targetDuration":359,"studyType":332,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":369,"locationsCount":370},"100362498","vertebral-artery-origin-treatment-via-endovascular-techniques-registry-voter-100362498","NCT03999983","Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)","VOTER","Inclusion Criteria:\n\n1. Patients between 18 and 90 years of age\n2. Patient has experienced a posterior circulation ischemic event\n3. Patient has angiographically confirmed bilateral vertebral artery origin disease (Hypoplasia, occlusion, or stenosis).\n4. Patient has \\>50% stenosis on the side being targeted for therapy\n\nExclusion Criteria:\n\n1. Pregnant women\n2. Contrast Indication to the use of anti-platelet drugs\n3. There is tandem vertebral or basilar artery stenosis\n4. The serum creatinin is \\>2.5\n5. Baseline modified Rankin score is \\>3\n6. \\\u003C 5 years life expectancy",{"count":358,"type":23},150,"1 Year","A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).",[362],"Vertebral Artery Stenosis","2025-02-10",{"date":365,"type":48},"2025-02-12",{"date":367,"type":48},"2019-11-19",{"date":163,"type":23},{"name":54,"class":55},10,""]